Carfilzomib for relapsed or refractory multiple myeloma

被引：0
|
作者：
Tanimoto, Tetsuya [1 ]
Tsuda, Kenji [2 ]
Oshima, Kumi [1 ]
Mori, Jinichi [1 ]
Shimmura, Hiroaki [1 ]
机构：
[1] Tokiwa Fdn, Jyoban Hosp, Fukushima 9728322, Japan
[2] Teikyo Univ, Chiba Med Ctr, Chiba, Japan
来源：
LANCET ONCOLOGY | 2018年 / 19卷 / 01期
关键词：
BONE-DISEASE; BISPHOSPHONATE;
D O I：
10.1016/S1470-2045(17)30859-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E1 / E1
页数：1
相关论文
共 50 条
  • [31] A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Feng, Lei
    Oriabure, Onyeka
    Graham, Vivian
    Chen, Wendy
    Badillo, Maria
    Lu, Rebecca
    Lee, Hun J.
    Jain, Preetesh
    Manasanch, Elisabet E.
    Orlowski, Robert Z.
    Wang, Michael L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) : E243 - E246
  • [32] Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
    Jain, Salvia
    Diefenbach, Catherine
    Zain, Jasmine
    O'Connor, Owen A.
    CORE EVIDENCE, 2011, 6 : 43 - 57
  • [33] IKEMA: Carfilzomib as the preferred combination with isatuximab in relapsed or refractory multiple myeloma patients?
    Cailly, Laura
    Leleu, Xavier
    Gruchet, Cecile
    HEMATOLOGIE, 2021, 27 (05): : 217 - 218
  • [34] Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
    Dimopoulos, M. A.
    Sonneveld, P.
    Siegel, D.
    Palumbo, A.
    San-Miguel, J.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2247 - 2256
  • [35] Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients
    Silvennoinen, Raija Helena
    Nahi, Hareth
    Anttila, Pekka
    Koskenvesa, Perttu
    Lievonen, Juha
    Marttila, Anu
    Varmavuo, Ville
    Sikio, Anu
    Nurmi, Marita
    Saily, Marjaana
    Partanen, Anu
    Sankelo, Marja
    Luoma, Sini
    Mantymaa, Pentti
    Ilveskero, Sorella
    Eshoj, Henrik Rode
    Nielsen, Lene Kongsgaard
    Jantunen, Esa
    Heckman, Caroline A.
    BLOOD, 2020, 136
  • [36] POPULATION PHARMACOKINETIC ANALYSIS OF CARFILZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA OR ADVANCED SOLID TUMORS
    Gunawan, R.
    Badros, A.
    Papadopoulos, K.
    Siegel, D.
    Jagannath, S.
    Vij, R.
    Niesvizky, R.
    Ou, Y.
    Wang, Z.
    Rajangam, K.
    Garnett, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S75 - S75
  • [37] A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
    Richard, Shambavi
    Jagannath, Sundar
    Cho, Hearn Jay
    Parekh, Samir
    Madduri, Deepu
    Richter, Joshua
    Chari, Ajai
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (01) : 31 - 45
  • [38] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
    Watanabe, Takashi
    Tobinai, Kensei
    Matsumoto, Morio
    Suzuki, Kenshi
    Sunami, Kazutaka
    Ishida, Tadao
    Ando, Kiyoshi
    Chou, Takaaki
    Ozaki, Shuji
    Taniwaki, Masafumi
    Uike, Naokuni
    Shibayama, Hirohiko
    Hatake, Kiyohiko
    Izutsu, Koji
    Ishikawa, Takayuki
    Shumiya, Yoshihisa
    Kashihara, Tomohisa
    Iida, Shinsuke
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
  • [39] BUDGET IMPACT ANALYSIS OF CARFILZOMIB FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA (MM) IN MEXICO
    Alva, M. E.
    Campioni, M.
    Zamora, J.
    Giannopoulou, A.
    VALUE IN HEALTH, 2015, 18 (07) : A818 - A818
  • [40] Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma
    Harvey, R. Donald
    Cong, Ze
    Werther, Winifred
    Lethen, Jan L.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
12345